Fig. 2
From: Enhanced glycolysis contributes to the pathogenesis of experimental autoimmune neuritis
2-DG inhibited the initiation of EAN. 2-DG (90 mg/rat) was intraperitoneally injected to BPM-induced EAN rats daily starting from the day of immunization to day 13 p.i. when the symptoms peaked. n = 4 in 2-DG group; n = 5 in the control group (one died of respiratory failure before the end point). Clinical scores (a) and body weight (b) were evaluated and recorded every day. *p < 0.05, **p < 0.01, ***p < 0.001. Sciatic nerves were harvested on day 13 p.i. for H&E staining (c) and CD68 immunostaining (d) (n = 4 in each group). The numbers of the total infiltrated mononuclear cells and macrophage (brown) at × 200 magnification were analyzed and displayed (***p < 0.001) (arrows denote the inflammatory mononuclear cells). The representative rats from both groups on day 12 p.i. were shown in (e). Compared with the 2-DG-treated rat, the rat from control group (arrowed) showed more serious weight loss and paralysis. The results are expressed as mean ± SD, two-tailed Student’s t test for unpaired data